Zealand Pharma A/s

Boehringer Ingelheim International Gmbh

Gb007, Inc.

Wolfgang Rist

Dieter Wolfgang Hamprecht

Ditte Riber

Jakob Lind Tolborg

Leo Thomas

Thorsten K Oost

Ralf Anderskewitz

Domnic Martyres

Peter Seither

Rasmus Just

Pia Nørregaard

Keld Fosgerau

Robert Augustin

Christoph Hoenke

Matthias Grauert

Thorsten Lehmann-Lintz

Peter Eickelmann

Steffen Breitfelder

Marc Grundl

Thomas Fox

Frank Buettner

Remko Alexander Bakker

Jan Magnus Kriegl

Pia Norregard

Pia NØRREGARD

ACYLATED GLUCAGON ANALOGUES

The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

Acylated glucagon analogues

The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

Glucagon analogues

The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

The present invention relates to pyrazole compounds of formula (I) and pharmaceutically acceptable salts thereof having CRTH2 antagonistic activity, wherein L, Y, Y, Y, Y, Y, Z, R, R, Rand n have one of the meanings as indicated in the specification and claims, to their use as medicaments, to pharmaceutical compositions containing said compounds and to pharmaceutical compositions containing said compounds in combination with one or more active substances. 

Pyrazole compounds as CRTH2 antagonists

The present invention relates to pyrazole compounds of formula (I) and pharmaceutically acceptable salts thereof having CRTH2-activity, wherein W, L, L, X, L, Y, Rand Rare as defined in the specification and claims, to their use as medicaments and to pharmaceutical formulations, containing said compounds or containing a combination of said compounds with one or more active substances.

The present invention relates to pyridazinone derivatives of general formula I, wherein the groups A, G and Rare as defined in the application, the tautomers thereof, stereoisomers thereof, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity. 

Benzoxazole- and tetrahydrobenzoxazole-substituted pyridazinones as GPR119 agonists

Pyrazole compounds of formula (Ia) or (Ib) and pharmaceutically acceptable salts thereof, wherein R, R, R, R, Y, Y, Y, Y, Y, Z, R, R, n and Rhave one of the meanings as indicated in the specification and claims, to their use as medicaments, to pharmaceutical formulations containing the compounds and to pharmaceutical formulations containing the compounds in combination with one or more active substances.

Growing community of inventors

Ingelheim am Rhein, Germany

Wolfgang Rist